The fibrinolysis system is responsible for removing blood clots. Hyperfibrinolysis describes a situation with markedly enhanced fibrinolytic activity, resulting in increased, sometimes catastrophic bleeding. Hyperfibrinolysis can be caused by acquired or congenital reasons. Among the congenital conditions for hyperfibrinolysis, deficiency of alpha 2 antiplasmin ref Carpenter SL, Mathew P. Alpha 2 antiplasmin and its deficiency fibrinolysis out of balance. Haemophilia, 2008 14 1250 4 ref alpha 2 plasmin inhibitor or plasminogen activator inhibitor type 1 PAI 1 ref Takahashi Y, Tanaka T, Minowa H et al. Hereditary partial deficiency of plasminogen activator inhibitor 1 associated with a lifelong bleeding tendency. Int J Hematol 1996 64 61 8 ref are very rare. The affected individuals show a hemophilia like bleeding phenotype. Acquired hyperfibrinolysis is found in liver disease , ref Goerlinger K. Coagulation management during liver transplantation. Haemostaseologie 2006 26 3 Suppl 1 S64 76 ref in patients with severe Physical trauma trauma , ref Levrat A, Gros A, Rugeri L, Inaba K, Floccard B, Negrier C, David JS. Evaluation of rotation thrombelastography for the diagnosis of hyperfibrinolysis ..., hyperfibrinolysis is associated with poor outcome. ref Sch chl H. Hyperfibrinolysis a prognostic ... polymerization and inhibit platelet aggregation. Moreover, plasmin which is formed in excess in hyperfibrinolysis ... and clot stability, may be a major cause for clinical bleeding. Diagnosis The diagnosis of hyperfibrinolysis ... time or thrombin time are not very sensitive for hyperfibrinolysis, and influenced by numerous ... hyperfibrinolysis very sensitively in a functional approach. The APTEM test, a tissue factor activated ... hyperfibrinolysis by comparing the TEM result of this assay with the EXTEM test same activator ... hyperfibrinolysis. ref Vorweg M, Hartmann B, Kn ttgen D, Jahn MC, Doehn M. Management of fulminant ..., the treatment or prophylaxis of hyperfibrinolysis is made with synthetic drugs such as tranexamic ... more details
Antifibrinolytics , such as aminocaproic acid aminocaproic acid and tranexamic acid are used as inhibitors of fibrinolysis ref DorlandsDict one 000006033 antifibrinolytic ref . These lysine like drugs interfere with the formation of the fibrinolytic enzyme plasmin from its precursor plasminogen by plasminogen activators primarily t PA and u PA which takes place mainly in lysine rich areas on the surface of fibrin. These drugs block the binding sites of the enzymes or plasminogen respectively and thus stop plasmin formation. They are used in menorrhagia and bleeding tendency due to various causes. Their application may be beneficial in patients with hyperfibrinolysis because they arrest bleeding rapidly if the other components of the haemostatic system are not severely affected. This may help to avoid the use of blood products such as fresh frozen plasma FFP with its associated risks of infections or anaphylactic reactions. The antifibrinolytic drug aprotinin was abandoned after identification of major side effects, especially on kidney. The indication for use of antifibrinolytic drugs is made with various methods. The most rapid and suitable one is thrombelastometry TEM in whole blood, which is even possible in patients on heparin . With various assays, an enhanced fibrinolysis becomes visible in the curve signature TEMogram and from the calculated values, e.g. the maximum lysis parameter. A special test for the identification of increased fibrinolysis APTEM compares the TEM in the absence or presence of the fibrinolysis inhibitor aprotinin . In severe cases of activated fibrinolysis, this assay confirms the syndrome already in less than 15 min during the early phases of clot formation ref Levrat A, Gros A, Rugeri L, Inaba K, Floccard B, Negrier C, David JS. Evaluation of rotation thrombelastography for the diagnosis of hyperfibrinolysis in trauma patients. Br J of Anaesthesia 2008 100 792 7. ref References reflist External links MeshName Antifibrinolytics MeshPha ... more details
of fibrinolytic activity, especially hyperfibrinolysis, is possible with thromboelastometry TEM ... thrombelastography for the diagnosis of hyperfibrinolysis in trauma patients. Br J Anaesthesia ... syndrome and various other disease states. However, acquired disturbance of fibrinolysis Hyperfibrinolysis ... factor and thus massive hyperfibrinolysis. ref Tieu BH, Holcomb JB, Schreiber MA. Coagulopathy Its ... disease states hyperfibrinolysis may occur. It could lead to massive bleeding if not diagnosed and treated ... in patients with hyperfibrinolysis because they arrest bleeding rapidly if the other components ... more details
time point or when the test has been stopped. A low LI X value or a high ML value indicates hyperfibrinolysis ... rapid loss of clot stability by hyperfibrinolysis may lead to bleeding complications which can be treated ... to EXTEM allows to detect fulminant hyperfibrinolysis. Therefore the test helps in identifying the necessity ... more details
PBB geneid 5327 Tissue plasminogen activator abbreviated TPA or PLAT is a protein involved in the breakdown of blood clot s. It is a serine protease EC number 3.4.21.68 found on endothelial cell s, the cells that line the blood vessel s. As an enzyme , it catalysis catalyzes the conversion of plasminogen to plasmin , the major enzyme responsible for clot breakdown. Because it works on the clotting system , tPA is used in clinical medicine to treat only embolic or thrombotic stroke . Use is contraindicated in hemorrhagic stroke and head trauma. tPA may be manufactured using Recombinant DNA recombinant Biotechnology Pharmaceutical products biotechnology techniques. tPA created this way may be referred to as recombinant tissue plasminogen activator rtPA . Function Image Fibrinolysis.png left thumb 250px A simplified illustration demonstrates clot breakdown fibrinolysis , with blue arrows denoting stimulation, and red arrows inhibition. The classic role of tPA is in the clotting system . To be specific, tPA catalyzes the conversion of plasminogen into plasmin . It does so by cleaving the single chain plasminogen into two chains. These two chains are linked by a disulfide bond and the resulting molecule is called plasmin. Increased enzymatic activity causes hyperfibrinolysis , which manifests as excessive bleeding. Decreased activity leads to hypofibrinolysis which can result in thrombosis or embolism . Tissue plasminogen activator also plays a role in cell migration and tissue remodeling . Genetics Tissue plasminogen activator is a protein encoded by the PLAT gene , which is located on chromosome 8 . The primary transcript produced by this gene undergoes alternative splicing , producing three distinct messenger RNA s. Clinical applications tPA is used in diseases that feature blood clot s, such as pulmonary embolism , myocardial infarction , and stroke , in a medical treatment called thrombolysis . To be effective in ischemic stroke, tPA must be administered within the ... more details
Encyclopedia
top
